AZN ▼ -0.6% - AstraZeneca PLC $AZN AstraZeneca: Phase 3 IMFINZI + Enfortumab Vedotin Cuts Death Risk by 42% and Event Risk by 49% in Muscle-Invasive Bladder Cancer ? • Overall Survival: 42% lower risk of death (HR 0.58), with 78% alive at two years vs. 69% with standard care. • Event-Free Survival: 49% lower risk of progression, recurrence, failure to undergo surgery or death (HR 0.51). Two-year EFS reached 64% vs. 45%. • Safety: Grade 3–4 adverse events occurred in 64% vs. 44%, with no new safety signals identified. • Regulatory: FDA granted Priority Review in September 2026 for cisplatin-ineligible patients or those declining cisplatin chemotherapy. 24-OCT-2026 10:41 AM ET